

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,  
Patent Owner

---

*Inter Partes* Review No.: IPR2021-00881

---

U.S. Patent No. 9,254,338 B2  
Filed: July 12, 2013  
Issued: February 9, 2016  
Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT  
ANGIOGENIC EYE DISORDERS

---

**EXPERT DECLARATION OF DR. THOMAS A. ALBINI  
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 9,254,338 B2**

## TABLE OF CONTENTS

	<u>Page</u>
I. QUALIFICATIONS AND BACKGROUND.....	1
A. Education and Experience.....	1
B. Bases for Opinions and Materials Considered.....	4
C. Scope of Work.....	4
II. LEGAL STANDARDS.....	4
III. PERSON OF ORDINARY SKILL IN THE ART.....	9
IV. SUMMARY OF OPINIONS.....	10
V. THE '338 PATENT (Ex.1001).....	12
A. Claim Construction.....	14
VI. BACKGROUND.....	19
A. Vitreoretinal Disorders.....	19
1. Age-related macular degeneration (AMD).....	20
2. Diabetic retinopathy (DR).....	22
3. Diabetic macular edema (DME).....	22
B. Angiogenesis and Vascular Endothelial Growth Factor (VEGF).....	22
C. VEGF Antagonists.....	23
D. VEGF Trap-Eye/Aflibercept.....	27
E. Regeneron's Press Releases and Clinical Trials.....	29
VII. SCOPE AND CONTENT OF THE PRIOR ART REFERENCES.....	35
A. Dixon (Ex.1006).....	35

**TABLE OF CONTENTS**  
**(continued)**

	<u>Page</u>
B. Adis (Ex.1007). .....	40
C. Regeneron (8-May-2008) (Ex.1013).....	43
D. NCT-795 (Ex.1014). .....	45
1. ClinicalTrials.gov.....	45
2. NCT-795 discloses the VIEW1 regimen. ....	48
E. NCT-377 (Ex.1015). .....	50
F. '664 Patent (Ex.1009). .....	53
G. '758 Patent (Ex.1010). .....	54
H. Dix (Ex.1033).....	55
VIII. UNPATENTABILITY OF THE '338 PATENT. ....	56
A. Claims 1, 3-11, 13, 14, 16-24, and 26 of the '338 Patent Are Anticipated by Dixon (Ex.1006). ....	56
1. Claim 1 of the '338 patent is anticipated by Dixon. ....	61
2. Dependent claims 3 and 4 are anticipated by Dixon. ....	64
3. Dependent claim 5 is anticipated by Dixon. ....	65
4. Dependent claims 6 and 7 are anticipated by Dixon. ....	66
5. Dependent claims 8-10 are anticipated by Dixon.....	67
6. Dependent claims 11 and 13 are anticipated by Dixon. ....	68
7. Independent claim 14 is anticipated by Dixon. ....	69
8. Dependent claims 16 and 17 are anticipated by Dixon. ....	70
9. Dependent claims 18 and 20 are anticipated by Dixon. ....	71

**TABLE OF CONTENTS**  
**(continued)**

	<u>Page</u>
10. Dependent claim 19 is anticipated by Dixon. ....	72
11. Dependent claims 21-23 are anticipated by Dixon. ....	73
12. Dependent claims 24 and 26 are anticipated by Dixon. ....	74
<b>B. Claims 1, 3-11, 13, 14, 16-24, and 26 of the '338 Patent Are Anticipated by Adis (Ex.1007). ....</b>	<b>75</b>
1. Claim 1 of the '338 patent is anticipated by Adis. ....	75
2. Dependent claims 3 and 4 are anticipated by Adis. ....	78
3. Dependent claim 5 is anticipated by Adis. ....	79
4. Dependent claims 6 and 7 are anticipated by Adis. ....	81
5. Dependent claims 8-10 are anticipated by Adis. ....	82
6. Dependent claims 11 and 13 are anticipated by Adis. ....	82
7. Independent claim 14 is anticipated by Adis. ....	83
8. Dependent claims 16 and 17 are anticipated by Adis. ....	84
9. Dependent claims 18 and 20 are anticipated by Adis. ....	85
10. Dependent claim 19 is anticipated by Adis. ....	86
11. Dependent claims 21-23 are anticipated by Adis. ....	87
12. Dependent claims 24 and 26 are anticipated by Adis. ....	87
<b>C. Claims 1, 3-11, 13, 14, 16-24, and 26 of the '338 Patent Are Anticipated by the Regeneron Press Release Dated May 8, 2008 (Regeneron (8-May-2008) (Ex.1013). ....</b>	<b>88</b>
1. Independent claim 1 of the '338 patent is anticipated by Regeneron (8-May-2008). ....	88

**TABLE OF CONTENTS**  
**(continued)**

	<u>Page</u>
2. Dependent claims 3 and 4 are anticipated by Regeneron (8-May-2008).....	91
3. Dependent claim 5 is anticipated by Regeneron (8-May-2008). .....	92
4. Dependent claims 6 and 7 are anticipated by Regeneron (8-May-2008).....	94
5. Dependent claims 8-10 are anticipated by Regeneron (8-May-2008).....	94
6. Dependent claims 11 and 13 are anticipated by Regeneron (8-May-2008).....	95
7. Independent claim 14 is anticipated by Regeneron (8-May-2008).....	96
8. Dependent claims 16 and 17 are anticipated by Regeneron (8-May-2008).....	97
9. Dependent claims 18 and 20 are anticipated by Regeneron (8-May-2008).....	98
10. Dependent claim 19 is anticipated by Regeneron (8-May-2008). .....	99
11. Dependent claims 21-23 are anticipated by Regeneron (8-May-2008).....	100
12. Dependent claims 24 and 26 are anticipated by Regeneron (8-May-2008).....	101
D. Claims 1, 3-11, 13, 14, 16-24, and 26 of the '338 Patent Are Anticipated by NCT00509795 (NCT-795) (Ex.1014).....	101
1. Independent claim 1 of the '338 patent is anticipated by NCT-795. ....	101
2. Dependent claims 3 and 4 are anticipated by NCT-795. ....	104

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.